SCHEMBL14246725

SCHEMBL14246725

Cc1ccc2c(c1)CCN=C2c1sc2ccccc2c1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 7/20 0.41
HPGD P15428 3/20 0.40
ALDH1A1 P00352 3/20 0.40
TP53 P04637 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 3/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GFER P55789 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
PTPN7 P35236 1/20 0.38
PTPN12 Q05209 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14317193 0.86 CA1 (0.47) MAPK10HPGDALDH1A1KMT2AHTT
SCHEMBL14246730 0.86 MAPK10 (0.40) MAPK10HPGDALDH1A1TP53KMT2A
SCHEMBL15931620 0.85 HTT (0.39) MAPK10HPGDALDH1A1TP53KMT2A
SCHEMBL15931658 0.85 ALDH1A1 (0.42) MAPK10HPGDALDH1A1TP53KMT2A
SCHEMBL12204215 0.81 MAPK10 (0.55) MAPK10HPGDALDH1A1KMT2AMEN1
SCHEMBL14246757 0.81 ALDH1A1 (0.39) MAPK10HPGDALDH1A1TP53KMT2A
SCHEMBL14246900 0.78 MAOA (0.44) MAPK10HPGDALDH1A1KMT2AHTT
SCHEMBL14246827 0.77 MAPK10 (0.51) MAPK10HPGDALDH1A1KMT2AMEN1
SCHEMBL14246743 0.77 CA1 (0.47) MAPK10HPGDALDH1A1KMT2AMEN1
SCHEMBL15931621 0.76 MAPK10 (0.45) MAPK10ALDH1A1HTTMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 MAPK10 958/4885HPGD 262/4885ALDH1A1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.